Publications
144
Citations
7,105
Est. group size
—
Recurring co-author estimate
Active years
23
Publishing since 2003
Eduardo Vilar-Gómez studies chronic liver diseases, with a focus on fatty liver disease driven by metabolic problems (recently termed MASLD, or metabolic dysfunction-associated steatotic liver disease). His work examines how factors such as body weight, type 2 diabetes, genetics, and alcohol consumption influence liver scarring (fibrosis) and disease progression, as well as the effects of diet and physical activity. He also investigates advanced liver disease outcomes like cirrhosis and liver cancer.
Publication activity has fluctuated year to year but remained substantial across the decade, averaging around nine papers per year over the last five years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Genetic and non-genetic drivers of histological progression and regression in MASLD
Journal of Hepatology · 2025
- SAT-226 Impact of infections on the natural history of compensated advanced chronic liver disease: data from an individual patient data meta-analysis
Journal of Hepatology · 2025
- SAT-225 Current incidence of decompensating events, HCC and their prognostic impact on patients with compensated advanced chronic liver disease
Journal of Hepatology · 2025
- Reply to correspondence on “Healthy eating and physical activity significantly lower sex-specific alcohol-attributable liver mortality in the United States”
Journal of Hepatology · 2025
- Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease
Annals of Hepatology · 2025
- THU-436 Histologic severity on liver biopsy is identical between normal weight and overweight adults with metabolic dysfunction associated steatotic liver disease: is it time to revise the definition of lean MASLD?
Journal of Hepatology · 2025
- Editorial: Enriching our understanding of <scp>MASLD</scp> through representation of under‐reported populations
Alimentary Pharmacology & Therapeutics · 2024
- Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease
Journal of Hepatology · 2024
- FRI-213 Low-to-moderate alcohol consumption is associated with increased fibrosis in subjects with metabolic dysfunction-associated steatotic liver disease
Journal of Hepatology · 2024
- Impact of low alcohol consumption in the natural history of cirrhosis
HepatoBiliary Surgery and Nutrition · 2024
- PNPLA3 rs738409, age, diabetes, sex, and advanced fibrosis jointly contribute to the risk of major adverse liver outcomes in metabolic dysfunction-associated steatotic liver disease
Hepatology · 2024
- Sa1553 METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) AND CLINICALLY SIGNIFICANT FIBROSIS ARE HIGHLY PREVALENT IN PCOS AND AN ALT &gt;19 U/L IS THE OPTIMAL CUT-OFF FOR IDENTIFYING MASLD IN PCOS
Gastroenterology · 2024
- Sa1567 METALD, THE NEW CATEGORY OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE (MASLD) - HOW COMMON IS IT?
Gastroenterology · 2024
- American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease
Hepatology Communications · 2023
- Physical Activity and Nonalcoholic Fatty Liver Disease: A Roundtable Statement from the American College of Sports Medicine
Medicine & Science in Sports & Exercise · 2023
- Journal of Hepatology×21
- Hepatology×12
- Gastroenterology×11
- Alimentary Pharmacology & Therapeutics×11
- Clinical Gastroenterology and Hepatology×9
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile